(33) conducted a phase II clinical trial to assess the therapeutic potential and associated toxicities of CD19/CD22-targeted CAR-T therapy combined with a decitabine-based lymphodepleting regimen in R/R DLBCL patients. This evidence concerns the gene CD22 and diffuse large B-cell lymphoma.